Several studies have been conducted to understand the role of targeting ASGPR for HCC after the proof-of-concept that demonstrated that GalNAc-conjugated siRNA specifically accumulated in the hepatocytes [206,207]. This evidence concerns the gene ASGR1 and hepatocellular carcinoma.